Navigation Links
WuXi PharmaTech Announces First-Quarter 2010 Results
Date:5/11/2010

6,209 4,239 Total current liabilities 66,832 80,337 Non-current liabilities: Long-term debt, excluding current portion 2,051 2,115 Advanced subsidies 1,333 1,420 Convertible notes 35,864 35,864 Other non-current liabilities 7,544 7,432 Total non-current liabilities 46,792 46,831 Total liabilities 113,624 127,168 Shareholders' equity: Ordinary shares ($0.02 par value, 5,002,550,000 authorized, 554,443,600 and 550,609,256 issued and outstanding as of March 31, 2010, and December 31, 2009, respectively) 11,089 11,012 Additional paid-in capital 323,024 320,672 Accumulated deficit (53,114) (68,631) Accumulated other comprehensive income 17,150 17,080 Total shareholders' equity 298,149 280,133 Total liabilities and shareholders' equity 411,773 407,301 WUXI PHARMATECH (CAYMAN) INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands of U.S. dollars, except ADS data and per ADS data) Three Months Ended March 31, 2010 2009 % Change Net revenues: Laboratory Services 66,998 56,596 18% Manufacturing Services 13,604 2,552 433% Total net revenues 80,602 59,148 36% Cost of revenues: Laboratory Serv
'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
2. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
3. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
4. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
5. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
6. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
7. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. Jazz Pharmaceuticals Announces Public Offering of Common Stock
10. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent
11. Somanetics Corporation Announces 24 Clinical Abstracts on INVOS System Presented at Annual Pediatric Academic Societies National Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Molecular Profiles Ltd., a subsidiary of ... Maryland -based Xceleron have announced a ... clinical development that will be launched at AAPS in ... This partnership extends Molecular Profiles, new ROADMAP to ... this month. The company also has complementary collaborations in ...
(Date:10/30/2014)... 30, 2014  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced an upcoming presentation ... candidate, aldoxorubicin.  The presentation, titled, "Drug Conjugates Bind ... given by Sant P. Chawla , M.D., ... principal investigator of the Company,s ongoing global, pivotal ...
(Date:10/30/2014)... October 30, 2014 , ... LGG contribuye a adquirir tolerancia a la proteína ... la proteína de la leche de la vaca (APLV) ... infancia. Hasta ahora, la APLV se trataba eliminando ... ha demostrado que es posible adquirir tolerancia oral ...
Breaking Medicine Technology:Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO ) today reported ... Total revenue was $2.4 million and $5.5 million for the three ... $2.5 million for the same periods in 2010. Total ... 2011, were $7.6 million and $15.0 million as compared to $6.1 ...
... 2011 CORRECTED -- Bionovo, Inc. (NASDAQ: BNVI ... the three months ended June 30, 2011. ... drug candidate, MF101, or Menerba™, during the past quarter, delivering ... and Chief Executive Officer. "We have completed the tasks which ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 9Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 10Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 11CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 2CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 3CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 4CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 5
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... New York (PRWEB) October 30, 2014 ... Society (NAMS) came to a close on Saturday, ... meeting since the Society’s inception in 1989. NAMS is ... health and quality of life of all women during ... healthy aging. With over 2,000 physicians and thought leaders ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. 29, 2014 (HealthDay ... may have effects on genital development in baby boys, a ... to moms with greater exposure to a chemical called DiNP ... between the genitals and anus. Anogenital distance is set in ... androgens ("male" hormones) during pregnancy. The researchers said their ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- A new vaccine ... meningococcal disease was approved by the U.S. Food and ... protect people between the ages of 10 and 25 ... serogroup B bacteria. The bacteria can infect ... spinal cord and brain. It is a leading cause ...
(Date:10/29/2014)... A new study has found that certain prostate cancer ... from heart-related causes in men with congestive heart failure ... , the findings will help doctors and patients weigh ... Androgen deprivation therapy (ADT), which reduces levels of male ... cancer cells, is a mainstay of treatment for prostate ...
Breaking Medicine News(10 mins):Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2
... FOREST, Ill., April 4, 2008 Hospira,Inc. (NYSE: ... today announced that it will host a conference call ... 2008, at 8 a.m. Central,Time., The company will ... stock market open and the conference call., A ...
... Nurses will hold,a news conference Tuesday, April 8, at ... importance of raising the Medicaid reimbursement rates to,help attract ... more,individuals to benefit from the service of care in ... health care services each,week -- equal to the combined ...
... for warning the public of the risk of a ... among law enforcement officers, according to a study by ... Health and the University of Medicine and Dentistry of ... Cop 2 Cop crisis intervention hotline found no statistically ...
... (Nasdaq: IDIX ) announced today that Idenix management,will ... the upcoming,Canaccord Adams Hepatitis C Conference on Wednesday, April ... Hotel in New York, NY., The live and ... "Calendar of Events" in the Idenix Investor Center at, ...
... Ohio) More than 600,000 children participate in school-sponsored ... Yet gymnastics continues to be overlooked in terms of ... injury rates of all girls sports. , A study, ... and Policy (CIRP) at The Research Institute at Nationwide ...
... 4, 2008 Dialysis,Corporation of America (Nasdaq: DCAI ... its eleventh facility in that state., President & ... our growth in Pennsylvania, one of our core markets ... superior quality,care for the patients we are responsible for ...
Cached Medicine News:Health News:Does raising the terrorism alert level cause undue stress? 2Health News:Dialysis Corporation of America Announces the Development of a New Facility in Pennsylvania 2
... Ankle Orthosis enables the clinician to ... ankle joint to control muscle imbalance ... a pair of bilateral turnbuckles, controlling ... Simply adjust the turnbuckle to gradually ...
... Protection,Protects the heel while maintaining the ankle ... contact with a soft, cushioning AliPlast™ foam ... and liner cradles the heel in a ... change position freely in bed from side-lying ...
... Pediatric Ankle Cryo/Cuff is specifically designed to ... Using a combination of controlled compression and ... pain. The Pediatric Ankle Cryo/Cuff is ideal ... episodes in hemophilia.,The Pediatric Ankle Cryo/Cuff is ...
SCD Sequential Compression System Intermittent Pneumatic Compression...
Medicine Products: